Umifenovir capsules 100mg, No. 20

• Prevention and treatment of influenza A and B, other acute respiratory viral infections in adults and children from 3 years old (for a dosage form of a capsule of 50 mg), from 6 years (for a dosage form of a capsule of 100 mg).

• Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years old (for a dosage form of a capsule of 50 mg), from 6 years (for a dosage form of a capsule of 100 mg).

• Complex therapy of recurrent herpes infection.

• Prevention of postoperative infectious complications.

Inside, before meals.

Single dose: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg (1 capsule of 100 mg or 2 capsules of 50 mg), over 12 years old and adults - 200 mg (2 capsules of 100 mg or 4 capsules of 50 mg).

For non-specific prevention and treatment of influenza and other acute respiratory viral infections in children and adults:

Non-specific prophylaxis:

During an epidemic of influenza and other acute respiratory viral infections: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg twice a week for 3 weeks.

In direct contact with patients with influenza and other acute respiratory viral infections: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg once a day for 10-14 days.

Treatment of influenza and other acute respiratory viral infections: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg 4 times a day (every 6 hours) for 5 days.

Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years old: from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old - 200 mg 4 times a day (every 6 hours) for 5 days ...

In the complex therapy of recurrent herpes infection: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.

Prevention of postoperative infectious complications: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg 2 days before surgery, then 2 and 5 days after surgery.

Taking the drug begins from the moment the first symptoms of influenza and other acute respiratory viral infections appear, preferably no later than 3 days from the onset of the disease.

If, after using the drug for three days in the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high fever (more than 38 ? C and more), persists, then you should consult a doctor to assess the feasibility of taking the drug.

Use the drug only according to the indications, the route of administration and the doses indicated in the instructions.

Active substance:

umifenovir hydrochloride monohydrate - 103.50 mg in terms of umifenovir hydrochloride - 100.00 mg.

Excipients: microcrystalline cellulose - 63.70 mg; potato starch - 33.00 mg; povidone-K25 - 11.00 mg; croscarmellose sodium - 4.40 mg; colloidal silicon dioxide - 2.20 mg; magnesium stearate - 2.20 mg

• Hypersensitivity to umifenovir or any component of the drug,

• children under 3 years of age (for a dosage form of 50 mg),

• age up to 6 years (for dosage form 100 mg),

• first trimester of pregnancy,

• breast-feeding.

  Carefully

  Second and third trimesters of pregnancy

pharmachologic effect

Antiviral agent. Specifically inhibits influenza A and B viruses, a coronavirus associated with severe acute respiratory syndrome. By the mechanism of antiviral action, it belongs to fusion inhibitors (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. Has a moderate immunomodulatory effect. It has interferon-inducing activity, stimulates humoral and cellular immune responses, phagocytic function of macrophages, increases the body's resistance to viral infections. Reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.

Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, a reduction in the duration of the disease, and a decrease in the risk of complications.

Refers to low-toxic compounds (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.

Pharmacokinetics

It is rapidly absorbed and distributed to organs and tissues. Cmax in blood plasma when taken at a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours.

It is metabolized in the liver. T1 / 2 is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.

Side effect

Rarely: allergic reactions.

special instructions

It does not show central neurotropic activity and can be used in medical practice for prophylactic purposes in practically healthy individuals of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).